ResearcherInsermNo recent work listed
Édouard Auclin
Matched on ORCID iD 0000-0001-7039-4840; OpenAlex author ID A5038686648. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper
Papers 5
- Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
- Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
- Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
- Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
- Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarci… First author DOI 10.1016/j.clinre.2019.03.007↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Julien Taı̈eb · 5 shared papers, 2019–2023 · strength 0.58
- Paper Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adeno… DOI 10.1016/j.ejca.2023.04.012↗
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Matthieu Sarabi · 3 shared papers, 2021–2022 · strength 0.36
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- David Tougeron · 3 shared papers, 2021–2022 · strength 0.36
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Sonia Zaibet · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Astrid Lièvre · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Dominique Béchade · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Julien Edeline · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Simon Pernot · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Marine Gilabert · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- António Sá Cunha · 2 shared papers, 2019–2021 · strength 0.18
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
- Jean‐Baptiste Bachet · 2 shared papers, 2019–2021 · strength 0.18
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Paper Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline an… DOI 10.1016/j.clinre.2019.03.007↗
- Caterina Vivaldi · 1 shared paper, 2023 · strength 0.14
- Lorenzo Pilla · 1 shared paper, 2023 · strength 0.14
- Anthony Turpin · 1 shared paper, 2023 · strength 0.14
- Volker Kunzmann · 1 shared paper, 2023 · strength 0.14
- Thibault Mazard · 1 shared paper, 2023 · strength 0.14
- Sara Lonardi · 1 shared paper, 2023 · strength 0.14
- Kathrin Heinrich · 1 shared paper, 2023 · strength 0.14
- Alice Boilève · 1 shared paper, 2023 · strength 0.14
- Monica Niger · 1 shared paper, 2023 · strength 0.14
- Gerald W. Prager · 1 shared paper, 2023 · strength 0.14
- Christoph Benedikt Westphalen · 1 shared paper, 2023 · strength 0.14
- Raëf Abdallah · 1 shared paper, 2021 · strength 0.10
- Léo Mas · 1 shared paper, 2021 · strength 0.10
- Angélique Vienot · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.